Upgrade to SI Premium - Free Trial

Avidity Biosciences Inc. (RNA)

8.00 +0.02 (0.25%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (12/2/26)
- M&A (3/31/15 *Est)

Latest Headlines

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) October 20, 2026 5:24 PM - PR NewsWire Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing October 20, 2026 8:09 AM - PR NewsWire Atrium Therapeutics (RNA) Reiterated at Overweight by Cantor Fitzgerald After Model Update October 15, 2026 7:51 AM - StreetInsider Atrium Therapeutics raises $50M in private placement October 8, 2026 6:30 AM - StreetInsider Atrium Therapeutics Announces $50 Million Private Placement October 8, 2026 6:30 AM - PR NewsWire Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) September 21, 2026 4:30 PM - PR NewsWire Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 20, 2026 6:24 PM - PR NewsWire Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18 August 14, 2026 5:47 AM - StreetInsider Atrium Therapeutics Reports Second Quarter 2026 Financial Results August 13, 2026 4:45 PM - PR NewsWire Atrium Therapeutics receives $15M milestone from Bristol Myers Squibb August 13, 2026 8:01 AM - StreetInsider Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration August 13, 2026 8:00 AM - PR NewsWire H.C. Wainwright Starts Atrium Therapeutics (RNA) at Buy August 6, 2026 6:09 AM - StreetInsider Full Article List